Onco Wiki / Disease

Malignant pleural mesothelioma (MPM)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-MESOTHELIOMA
TypeDisease
Aliases
Malignant mesotheliomaMesothelioma NOSPeritoneal mesotheliomaЗлоякісна мезотеліома плеври
Statusreviewed 2026-05-04 | pending_clinical_signoff
DiseasesNone declared
SourcesNone declared

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9050/3
icd_o_3_topography["C38.4", "C48.1", "C48.2"]
icd_10C45.0
who_classificationWHO Thoracic Tumours 5th ed (2021): Mesothelioma

Capabilities

Notes

Malignant mesothelioma is predominantly a pleural cancer (MPM ~80% of cases); peritoneal mesothelioma (~20%) has different treatment (cytoreductive surgery + hyperthermic intraperitoneal chemotherapy [HIPEC] for peritoneal). This disease entity focuses on MPM. Historically extremely poor prognosis (mOS ~12 mo); CheckMate-743 (FDA 2020) with nivolumab+ipilimumab improved mOS to 18.1 mo — first new 1L approval in 15 years. BAP1 IHC loss is a diagnostic marker (not actionable therapeutically). PD-L1 expression is not validated as predictive for ICI benefit in MPM.

Used By

Algorithms

Disease

Indication

Questionnaires

Red flag

Regimen

Sources